It's Probably Less Likely That Petros Pharmaceuticals, Inc.'s (NASDAQ:PTPI) CEO Will See A Huge Pay Rise This Year

Simply Wall St.11-13

Key Insights Petros Pharmaceuticals to hold its Annual General Meeting on 20th of November Total pay for CEO Fady Boctor includes US$350.0k salary The total compensation is similar to the average ...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2483830832?lang=en_US&edition=fundamental","thumbnail":"https://images.simplywall.st/asset/industry/6121000-choice2-main-header/1585186699299","is_english":true,"pubTime":"2024-11-13 20:00","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2483830832","market":"us","top_or_hot":-1,"title":"It's Probably Less Likely That Petros Pharmaceuticals, Inc.'s (NASDAQ:PTPI) CEO Will See A Huge Pay Rise This Year","media":"Simply Wall St.","content":"<div>\n<p>Key Insights Petros Pharmaceuticals to hold its Annual General Meeting on 20th of November   Total pay for CEO Fady Boctor includes US$350.0k salary   The total compensation is similar to the average ...</p>\n\n<a href=\"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-ptpi/petros-pharmaceuticals/news/its-probably-less-likely-that-petros-pharmaceuticals-incs-na\">Source Link</a>\n\n</div>\n","source":"simplywall_highlight","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>It's Probably Less Likely That Petros Pharmaceuticals, Inc.'s (NASDAQ:PTPI) CEO Will See A Huge Pay Rise This Year</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nIt's Probably Less Likely That Petros Pharmaceuticals, Inc.'s (NASDAQ:PTPI) CEO Will See A Huge Pay Rise This Year\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-11-13 20:00 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-ptpi/petros-pharmaceuticals/news/its-probably-less-likely-that-petros-pharmaceuticals-incs-na><strong>Simply Wall St.</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Key Insights Petros Pharmaceuticals to hold its Annual General Meeting on 20th of November   Total pay for CEO Fady Boctor includes US$350.0k salary   The total compensation is similar to the average ...</p>\n\n<a href=\"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-ptpi/petros-pharmaceuticals/news/its-probably-less-likely-that-petros-pharmaceuticals-incs-na\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"NDAQ","symbol_name":"纳斯达克OMX交易所","start_time":0,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-ptpi/petros-pharmaceuticals/news/its-probably-less-likely-that-petros-pharmaceuticals-incs-na","article_id":"2483830832","we_media_id":null,"thumbnails":["https://images.simplywall.st/asset/industry/6121000-choice2-main-header/1585186699299"],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2483830832","pubTimestamp":1731499233,"sourceInfo":{"source_id":"simplywall_highlight","name":"Simply Wall St."},"weMediaInfo":null,"summary":"Key Insights Petros Pharmaceuticals to hold its Annual General Meeting on 20th of November Total pay for CEO Fady...","collect":0,"end_time":0,"defaultTopTitle":"simplywall.st","property":[],"viewcount":null,"language":"en","relate_stocks":{"NDAQ":"纳斯达克OMX交易所","LU2210150020.SGD":"Natixis Thematics Subscription Economy R/A SGD","IE00B64PRP62.GBP":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (GBP) ACC","BK4585":"ETF&股票定投概念","LU2210149790.SGD":"Natixis Thematics Subscription Economy R/A SGD-H","IE00BKPKM429.USD":"NEUBERGER BERMAN GLOBAL SUSTAINABLE EQUITY \"A\" (USD) ACC","QID":"纳指两倍做空ETF","BK4007":"制药","IE00BGHQF748.EUR":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (EUR) ACC","IE00B3QW5Z07.USD":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (USD) ACC","BK4588":"碎股","SQQQ":"纳指三倍做空ETF",".IXIC":"NASDAQ Composite","QLD":"纳指两倍做多ETF","PTPI":"Petros Pharmaceuticals Inc","PSQ":"纳指反向ETF","BK4112":"金融交易所和数据","LU2095319765.USD":"Natixis Thematics Subscription Economy R/A USD","TQQQ":"纳指三倍做多ETF"},"translate_title":"Petros Pharmaceuticals，Inc.（纳斯达克：PTPI）首席执行官今年大幅加薪的可能性可能较小","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"PTPI":1,"NDAQ":1,".IXIC":1,"TQQQ":0.6,"SQQQ":0.6,"QLD":0.6,"QID":0.6,"PSQ":0.6,"NQmain":0.6,"MNQmain":0.6},"content_text":"Key Insights Petros Pharmaceuticals to hold its Annual General Meeting on 20th of November   Total pay for CEO Fady Boctor includes US$350.0k salary   The total compensation is similar to the average for the industry   Over the past three years, Petros Pharmaceuticals' EPS grew by 8.5%  and over the past three years, the total loss to shareholders 98%   Shareholders of Petros Pharmaceuticals, Inc. (NASDAQ:PTPI) will have been dismayed by the negative share price return over the last three years.    Despite positive EPS growth in the past few years, the share price hasn't tracked the fundamental performance of the company.  The AGM coming up on the 20th of November could be an opportunity for shareholders to bring these concerns to the board's attention.  They could also influence management through voting on resolutions such as executive remuneration.  Here's our take on why we think shareholders may want to be cautious of approving a raise for the CEO at the moment.      See our latest analysis for Petros Pharmaceuticals  How Does Total Compensation For Fady Boctor Compare With Other Companies In The Industry?  At the time of writing, our data shows that Petros Pharmaceuticals, Inc. has a market capitalization of US$2.9m, and reported total annual CEO compensation of US$875k for the year to December 2023.   That's a notable increase of 28% on last year.    We think total compensation is more important but our data shows that the CEO salary is lower, at US$350k.   On comparing similar-sized companies in the American Pharmaceuticals industry with market capitalizations below US$200m, we found that the median total CEO compensation was US$875k.     From this we gather that Fady Boctor is paid around the median for CEOs in the industry.  Component20232022Proportion (2023)Salary US$350k US$350k 40% Other US$525k US$332k 60% Total CompensationUS$875k US$682k100% On an industry level, roughly 28% of total compensation represents salary and 72% is other remuneration.    It's interesting to note that Petros Pharmaceuticals pays out a greater portion of remuneration through salary, compared to the industry.    If non-salary compensation dominates total pay, it's an indicator that the executive's salary is tied to company performance.  NasdaqCM:PTPI CEO Compensation November 13th 2024 Petros Pharmaceuticals, Inc.'s Growth  Petros Pharmaceuticals, Inc. has seen its earnings per share (EPS) increase by 8.5% a year over the past three years.     Its revenue is up 7.0% over the last year.    We'd prefer higher revenue growth,  but we're happy with the modest EPS growth.  Considering these factors we'd say performance has been pretty decent, though not amazing.      Moving away from current form for a second, it could be important to check this free visual depiction of what analysts expect for the future.  Has Petros Pharmaceuticals, Inc. Been A Good Investment? With a total shareholder return of -98% over three years, Petros Pharmaceuticals, Inc. shareholders would by and large be disappointed.   This suggests it would be unwise for the company to pay the CEO too generously.    To Conclude...  Shareholders have not seen their shares grow in value, rather they have seen their shares decline.  A huge lag in share price growth when earnings have grown may indicate there could be other issues that are affecting the company at the moment that the market is focused on.  Shareholders would probably be keen to find out what are the other factors could be weighing down the stock.  At the upcoming AGM, shareholders will get the opportunity to discuss any issues with the board, including those related to CEO remuneration and assess if the board's plan will likely improve performance in the future.      We can learn a lot about a company by studying its CEO compensation trends, along with looking at other aspects of the business.  That's why we did our research, and identified 6 warning signs for Petros Pharmaceuticals (of which 3 are concerning!) that you should know about in order to have a holistic understanding of the stock.    Of course, you might find a fantastic investment by looking at a different set of stocks. So take a peek at this free list of interesting companies.  New: Manage All Your Stock Portfolios in One PlaceWe've created the ultimate portfolio companion for stock investors, and it's free.• Connect an unlimited number of Portfolios and see your total in one currency• Be alerted to new Warning Signs or Risks via email or mobile• Track the Fair Value of your stocksTry a Demo Portfolio for FreeHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.","kind":null,"is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.29.2","shortVersion":"4.29.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2483830832"}